1
|
Wang H, Ma J, Lu J, Wang Y, Zhang B, Zhang H, Peng H. TMB is associated with the prognosis of egfr-mutated non-small cell lung cancer in Xuanwei, China. Biomark Med 2024; 18:1123-1133. [PMID: 39633593 DOI: 10.1080/17520363.2024.2432306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Accepted: 11/18/2024] [Indexed: 12/07/2024] Open
Abstract
AIMS Study on the prognostic characteristics and biomarkers of lung cancer in Xuanwei Patients. MATERIALS AND METHODS A retrospective analysis was conducted on the genetic data of 261 NSCLC patients, as well as the prognostic data of 133 patients. The relationship between prognosis and EGFR mutations in the Xuanwei and non Xuanwei cohorts was compared and analyzed. RESULTS The superior progression-free survival (PFS) in Xuanwei patients was primarily observed in those with EGFR-mutated tumors (p < 0.05). Further analysis of accompanying mutations and TMB levels revealed an association between high TMB and a favorable prognosis in EGFR-mutated Xuanwei NSCLC. CONCLUSION Xuanwei lung cancer differs from non Xuanwei patients in terms of prognosis and tumor mutation burden, and further research should be conducted.
Collapse
Affiliation(s)
- Han Wang
- Department of Thoracic Surgery, The First People's Hospital of Yunnan Province, Kunming City, Yunnan Province, P.R. China
| | - Junrui Ma
- School of Nursing, Yunnan University of Traditional Chinese Medicines, Kunming City, Yunnan Province, P.R. China
| | - Jiagui Lu
- Department of Thoracic Surgery, The First People's Hospital of Yunnan Province, Kunming City, Yunnan Province, P.R. China
| | - Yang Wang
- Department of Thoracic Surgery, The First People's Hospital of Yunnan Province, Kunming City, Yunnan Province, P.R. China
| | - Binli Zhang
- Department of Thoracic Surgery, The First People's Hospital of Yunnan Province, Kunming City, Yunnan Province, P.R. China
| | - Hushan Zhang
- Key Laboratory of Northeastern Yunnan Natural Medicine, Zhaotong Healthy Vocational College, Zhaotong City, Yunnan Province, China
- Anning First People's Hospital Affiliated to Kunming University of Science and Technology, Kunming, Yunnan, P.R. China
- The Medical Department, 3D Medicines Inc, Shanghai, P.R. China
| | - Hao Peng
- Department of Thoracic Surgery, The First People's Hospital of Yunnan Province, Kunming City, Yunnan Province, P.R. China
| |
Collapse
|
2
|
Zhang T, Hu Y, Yang N, Yu S, Pu X. The microRNA-34 Family and Its Functional Role in Lung Cancer. Am J Clin Oncol 2024; 47:448-457. [PMID: 38700126 PMCID: PMC11340685 DOI: 10.1097/coc.0000000000001106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/05/2024]
Abstract
Lung cancer is one of the most common malignant tumors in humans and the leading cause of cancer-related deaths worldwide. The microRNA-34 (miR-34) family is dysregulated in various human cancers and is an important family of tumor suppressor genes among microRNAs. The miR-34 family is downregulated in lung cancer. It inhibits cell proliferation, metastasis, and invasion, arrests the cell cycle, and induces apoptosis or senescence by negatively regulating many oncogenes. It is commonly used to detect and treat lung cancer. This study describes the regulatory role of the miR-34 family in lung cancer and the associated research advances in treatment.
Collapse
Affiliation(s)
| | | | - Na Yang
- Department of Clinical Pharmacy, The Second People’s Hospital of Huaihua, Huaihua
| | - Shaofu Yu
- Department of Clinical Pharmacy, The Second People’s Hospital of Huaihua, Huaihua
| | - Xingxiang Pu
- The Second Department of Thoracic Medical Oncology, Hunan Cancer Hospital, Changsha, Hunan, China
| |
Collapse
|
3
|
Wang Y, Zhang T, He X. Advances in the role of microRNAs associated with the PI3K/AKT signaling pathway in lung cancer. Front Oncol 2023; 13:1279822. [PMID: 38169723 PMCID: PMC10758458 DOI: 10.3389/fonc.2023.1279822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2023] [Accepted: 12/05/2023] [Indexed: 01/05/2024] Open
Abstract
Cancer has long been a topic of great interest in society and a major factor affecting human health. Breast, prostate, lung, and colorectal cancers are the top four tumor types with the greatest incidence rates in 2020, according to the most recent data on global cancer incidence. Among these, lung cancer had the highest fatality rate. Extensive research has shown that microRNAs, through different signaling pathways, play crucial roles in cancer development. It is considered that the PI3K/AKT signaling pathway plays a significant role in the development of lung cancer. MicroRNAs can act as a tumor suppressor or an oncogene by altering the expression of important proteins in this pathway, such as PTEN and AKT. In order to improve the clinical translational benefit of microRNAs in lung cancer research, we have generalized and summarized the way of action of microRNAs linked with the PI3/AKT signaling pathway in this review through literature search and data analysis.
Collapse
Affiliation(s)
- Yanting Wang
- The First School of Clinical Medicine, Gannan Medical University, Ganzhou, China
- Department of Respiratory and Critical Illness Medicine, Gannan Medical University’s First Affiliated Hospital, Ganzhou, China
| | - Tao Zhang
- The First School of Clinical Medicine, Gannan Medical University, Ganzhou, China
| | - Xin He
- Department of Respiratory and Critical Illness Medicine, Gannan Medical University’s First Affiliated Hospital, Ganzhou, China
- Jiangxi Provincial Branch of China Clinical Medical Research Center for Geriatric Diseases, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China
| |
Collapse
|
4
|
El-Arabey A, Abdel-Hamied H, Awadalla M, Alosaimi B, Almanaa T, Al-Shouli S, Modafer Y, Alhamdi H, Abdalla M. A bioinformatic analysis of the role of TP53 status on the infiltration of CD8+ T cells into the tumor microenvironment. Braz J Med Biol Res 2023; 56:e12970. [PMID: 37878888 PMCID: PMC10591486 DOI: 10.1590/1414-431x2023e12970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Accepted: 08/27/2023] [Indexed: 10/27/2023] Open
Abstract
CD8+ T cells play basic roles in the immune system in a tumor microenvironment (TME) to fight cancer. Several reports have suggested signs of the involvement of tumor protein p53 (TP53) in a complex immune system network. Moreover, our previous research indicated that TP53 orchestrates the polarization and infiltration of macrophages into the TME. In the present study, the clinical function of TP53 status (wild/mutant) in CD8+ T cell infiltration was assessed using more than 10,000 The Cancer Genome Atlas (TCGA) samples from 30 cancer types through Tumor Immune Estimation (TIMER). Our investigation revealed that CD8+ T cell infiltration was higher in head and neck squamous cell carcinoma (HNSC) and uterine corpus endometrial carcinoma (UCEC) patients with wild-type TP53 than in those with mutant TP53. Wild-type TP53 conferred a good prognosis for HNSC and UCEC (P<0.05). In contrast, CD8+ T cell infiltration in lung adenocarcinoma (LUAD) patients with wild-type TP53 was much lower than in those with mutant TP53. Notably, clinical outcomes for LUAD with wild-type TP53 were poor (P<0.05). This study was the first to provide insights into the novel association of TP53 with CD8+ T cells infiltration in the TME in patients with HNSC, LUAD, and UCEC. Therefore, TP53 status acts as a prognostic marker, and this can be used as a basis to further study the effect of targeting TP53 in these patients. Furthermore, our study found that TP53 status was a reliable predictive factor and therapeutic target in patients with HNSC and UCEC.
Collapse
Affiliation(s)
- A.A. El-Arabey
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt
| | - H.E. Abdel-Hamied
- Department of General Pathology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
| | - M.E. Awadalla
- Research Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia
| | - B. Alosaimi
- Research Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh, Saudi Arabia
| | - T.N. Almanaa
- Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia
| | - S.T. Al-Shouli
- Immunology Unit, Department of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Y.A. Modafer
- Department of Biology, Faculty of Science, Jazan University, Jazan, Saudi Arabia
| | - H.W. Alhamdi
- Department of Biology, College of Sciences, King Khalid University, Abha, Saudi Arabia
| | - M. Abdalla
- Pediatric Research Institute, Children's Hospital Affiliated to Shandong University, Jinan, Shandong, China
| |
Collapse
|
5
|
Tang M, Chen J, Zeng T, Ye DM, Li YK, Zou J, Zhang YP. Systemic analysis of the DNA replication regulator origin recognition complex in lung adenocarcinomas identifies prognostic and expression significance. Cancer Med 2023; 12:5035-5054. [PMID: 36205357 PMCID: PMC9972100 DOI: 10.1002/cam4.5238] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Revised: 07/30/2022] [Accepted: 09/01/2022] [Indexed: 11/11/2022] Open
Abstract
BACKGROUND DNA replication alteration is a hallmark of patients with lung adenocarcinoma (LUAD) and is frequently observed in LUAD progression. Origin recognition complex (ORC) 1, ORC2, ORC3, ORC4, ORC5, and ORC6 form a replication-initiator complex to mediate DNA replication, which plays a key role in carcinogenesis, while their roles in LUAD remain poorly understood. METHODS The mRNA and protein expression of ORCs was confirmed by the GEPIA, HPA, CPTAC, and TCGA databases. The protein-protein interaction network was analyzed by the GeneMANIA database. Functional enrichment was confirmed by the Metascape database. The effects of ORCs on immune infiltration were validated by the TIMER database. The prognostic significance of ORCs in LUAD was confirmed by the KM-plot and GENT2 databases. DNA alteration and protein structure were determined in the cBioProtal and PDB databases. Moreover, the protein expression and prognostic value of ORCs were confirmed in our LUAD data sets by immunohistochemistry (IHC) staining. RESULTS ORC mRNA and protein were significantly increased in patients with LUAD compared with corresponding normal tissue samples. The results of IHC staining analysis were similar result to those of the above bioinformatics analysis. Furthermore, ORC1 and ORC6 had significant prognostic values for LUAD patients. Furthermore, the ORC cooperatively promoted LUAD development by driving DNA replication, cellular senescence, and metabolic processes. CONCLUSION The ORC, especially ORC1/6, has important prognostic and expression significance for LUAD patients.
Collapse
Affiliation(s)
- Min Tang
- Department of Cardiothoracic Surgery, The Second Affiliated Hospital of University of South China, Hengyang, Hunan, People's Republic of China
| | - Juan Chen
- Department of Radiotherapy, The Second Affiliated Hospital of University of South China, Hengyang, Hunan, People's Republic of China
| | - Tian Zeng
- Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, University of South China, Hengyang, Hunan, People's Republic of China
| | - Dong-Mei Ye
- Department of Pathology, The First Hospital of Nanchang City, Nanchang, Jiangxi, People's Republic of China
| | - Yu-Kun Li
- Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, University of South China, Hengyang, Hunan, People's Republic of China
| | - Juan Zou
- Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, University of South China, Hengyang, Hunan, People's Republic of China
| | - Yu-Ping Zhang
- Department of Cardiothoracic Surgery, The Second Affiliated Hospital of University of South China, Hengyang, Hunan, People's Republic of China
| |
Collapse
|
6
|
Xu L, Huang X, Lou Y, Xie W, Zhao H. Regulation of apoptosis, autophagy and ferroptosis by non‑coding RNAs in metastatic non‑small cell lung cancer (Review). Exp Ther Med 2022; 23:352. [PMID: 35493430 PMCID: PMC9019694 DOI: 10.3892/etm.2022.11279] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2022] [Accepted: 03/10/2022] [Indexed: 11/06/2022] Open
Abstract
Non-small cell lung cancer (NSCLC), a common type of cancer worldwide, is normally associated with a poor prognosis. It is difficult to treat successfully as it often metastasizes into brain or bone. Methods to facilitate the induction of effective programmed cell death (PCD) in NSCLC cells to reverse drug resistance, or to inhibit the invasion and migration of NSCLC cells, are currently under investigation. The present study summarized the regulatory functions of PCD, including apoptosis, autophagy and ferroptosis, in the context of NSCLC metastasis. It further summarized how regulatory agents, including long non-coding RNAs, circular RNAs and microRNAs, regulate PCD during the metastasis of NSCLC and characterized new potential diagnostic biomarkers of NSCLC metastasis.
Collapse
Affiliation(s)
- Lei Xu
- Department of Orthopedics, Chengdu Seventh People's Hospital, Chengdu, Sichuan 610213, P.R. China
| | - Xin Huang
- Department of Orthopedics, Chengdu Seventh People's Hospital, Chengdu, Sichuan 610213, P.R. China
| | - Yan Lou
- Department of Orthopedic Oncology, Spine Tumor Center, Changzheng Hospital, Naval Military Medical University, Shanghai 200003, P.R. China
| | - Wei Xie
- Department of Orthopedics, Chengdu Seventh People's Hospital, Chengdu, Sichuan 610213, P.R. China
| | - Hangyu Zhao
- Department of Orthopedics, Chengdu Seventh People's Hospital, Chengdu, Sichuan 610213, P.R. China
| |
Collapse
|